Exercise News and Research

Latest Exercise News and Research

Modified Citrus Pectin holds promise against prostate cancer

Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the most recent publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner.

2 Jul 2010

Javelin announces successful completion of tender offer by Hospira subsidiary

Javelin Pharmaceuticals, Inc., today announced the successful completion of the tender offer by Discus Acquisition Corporation, a wholly owned subsidiary of Hospira, Inc., to purchase all outstanding shares of the common stock of Javelin.

2 Jul 2010

Research may provide key to understanding interplay between exercise, aging and neurogenesis

Stem cells in the brain remain dormant until called upon to divide and make more neurons. However, little has been known about the molecular guards that keep them quiet.

2 Jul 2010

Clinical study proves effectiveness of acupuncture for heart patients

Acupuncture can improve exercise tolerance in patients suffering from chronic heart failure. This was determined in a clinical pilot study by the team headed by Dr. Johannes Backs, physician and study director at the Department of Internal Medicine III (Cardiology, Angiology, and Pneumology - Medical Director: Professor Dr. Hugo Katus) of Heidelberg University Hospital.

2 Jul 2010

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

United Therapeutics Corporation and Lee's Pharmaceutical Holdings Ltd. announced today that they have entered into an exclusive agreement for the distribution of Remodulin (treprostinil) Injection in China. Remodulin is a subcutaneously or intravenously administered prostacyclin analogue for the treatment of pulmonary arterial hypertension. Lee's Pharmaceutical is a leading Chinese pharmaceutical company with both a strong cardiovascular focus and extensive commercialization experience.

2 Jul 2010

Hospira subsidiary completes tender offer for Javelin's outstanding shares of common stock

Hospira, Inc., a global specialty pharmaceutical and medication delivery company, today announced the successful completion of the tender offer by Discus Acquisition Corporation, a wholly owned Hospira subsidiary, to purchase all outstanding shares of the common stock of Javelin Pharmaceuticals, Inc..

1 Jul 2010

Advanced Life Sciences prices securities offering

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has established the pricing terms of its proposed offering of units.

1 Jul 2010

Bacterin International completes reverse merger transaction

Bacterin International, Inc., a Nevada company, today announced that it has completed a reverse merger transaction with Bacterin International Holdings, Inc. f/k/a K-Kitz, in which the Company caused its wholly-owned subsidiary to be merged with and into Bacterin, with Bacterin as the surviving company.

1 Jul 2010

Advancements in total hip replacement procedure make young patients opt for surgery

Traditionally, total hip replacement surgery was performed on the elderly, but these days, advancements in the procedure have patients opting for the surgery much earlier in life.

1 Jul 2010

New guide to get pregnant

Infertility affects about 7 million Americans -- that's about one in six couples during their childbearing years. There are many reasons for infertility, with equal chances it's his medical issue as it is hers. A new book, "A Baby at Last!: The Couples' Complete Guide to Getting Pregnant" (Fireside Books, Simon and Schuster), points the way for couples to get past the emotionally wrenching obstacle of infertility and finally bring home their bundle of joy.

1 Jul 2010

Rexahn closes sale of $10 million of securities in registered direct offering

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the closing of a previously announced sale of an aggregate of $10 million of securities in a registered direct offering. Rexahn received net proceeds of approximately $9.28 million after deducting placement agent fees and other offering expenses.

1 Jul 2010

pSivida's licensee submits NDA to FDA for Iluvien

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a New Drug Application to the U.S. Food and Drug Administration for Iluvien for Diabetic Macular Edema.

1 Jul 2010

Neuralstem announces completion of $10 million registered direct offering

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed its previously announced registered direct offering of $10 million of units to institutional investors. The units were priced at $2.80 and consisted of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $9.2 million. All of the securities were offered pursuant to an effective shelf registration statement.

1 Jul 2010

Prasco commences shipments of generic prescription ZEGERID Capsules

Santarus, Inc., a specialty biopharmaceutical company, today announced that pursuant to its distribution and supply agreement with Prasco, LLC, Prasco is commencing shipments of an authorized generic of prescription ZEGERID® (omeprazole/ sodium bicarbonate) Capsules in 20 mg and 40 mg dosage strengths in the U.S. under the Prasco label. ZEGERID is an immediate-release proton pump inhibitor (PPI) approved as a prescription product in the U.S. for the treatment of certain upper gastrointestinal diseases and disorders.

1 Jul 2010

Blue Shield of California offers SilverSneakers Fitness Program to Medicare Supplement Plan subscribers

Blue Shield of California is now offering the Healthways SilverSneakers® Fitness Program to subscribers of Blue Shield Medicare Supplement Plans throughout California. SilverSneakers, the nation's leading social support and exercise program designed to keep seniors healthy, has been a popular benefit with California Medicare HMOs, but Blue Shield is one of the few health plans in the state to offer the benefit as part of its Medicare Supplement plans as well.

30 Jun 2010

Grifols to acquire Pharmalink's Xepol programme for post-polio syndrome

Pharmalink AB, today announced that it has closed its agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R) programme for the treatment of post-polio syndrome (PPS). The parties had previously announced reaching an agreement whereby Grifols would acquire all know-how and global intellectual property rights related to the use of human immunoglobulin for the treatment of (PPS) - the concept at the heart of the Xepol programme.

30 Jun 2010

Yayi International net sales decrease 25.0% to $7.0M for five months ended March 31, 2010

Yayi International Inc.,, the first mover and a leading producer and distributor of premium goat milk formula products for infants, toddlers, young children, and adults in the People's Republic of China, today announced its financial results for the transition period from November 1, 2009 to March 31, 2010.

30 Jun 2010

Humana launches ‘Points of Caregiving’ program

Humana Inc. today introduced Points of Caregiving, a comprehensive resource for the nation's 52 million caregivers. Designed as a complete caregiver's destination, the program includes an easy-to-use interactive website, telephonic support and customized reminders to help caregivers make decisions with confidence and to find support from peers.

30 Jun 2010

Medivir's rights issue changes number of shares and votes

The number of shares and the number of votes in Medivir have changed as a result of the rights issue carried out by the company as well as the exercise of employee stock options.

30 Jun 2010

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

New long term data showed that Vimpat- (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy. In addition post-hoc exploratory analyses showed that adjunctive lacosamide treatment reduced partial-onset seizure frequency and improved responder rates when added to a broad range of antiepileptic drugs (AEDs) including both traditional sodium channel-blocking agents and those that act on non-sodium channel-targets.

30 Jun 2010

Exercise News and Research

Latest Exercise News and Research

Modified Citrus Pectin holds promise against prostate cancer

Javelin announces successful completion of tender offer by Hospira subsidiary

Research may provide key to understanding interplay between exercise, aging and neurogenesis

Clinical study proves effectiveness of acupuncture for heart patients

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

Hospira subsidiary completes tender offer for Javelin's outstanding shares of common stock

Advanced Life Sciences prices securities offering

Bacterin International completes reverse merger transaction

Advancements in total hip replacement procedure make young patients opt for surgery

New guide to get pregnant

Rexahn closes sale of $10 million of securities in registered direct offering

pSivida's licensee submits NDA to FDA for Iluvien

Neuralstem announces completion of $10 million registered direct offering

Prasco commences shipments of generic prescription ZEGERID Capsules

Blue Shield of California offers SilverSneakers Fitness Program to Medicare Supplement Plan subscribers

Grifols to acquire Pharmalink's Xepol programme for post-polio syndrome

Yayi International net sales decrease 25.0% to $7.0M for five months ended March 31, 2010

Humana launches ‘Points of Caregiving’ program

Medivir's rights issue changes number of shares and votes

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Exercise News and Research

Latest Exercise News and Research

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Newsletters you may be interested in